Initial assessment
When choosing a non-steroidal anti-inflammatory drug (NSAID), the initial assessment should integrate the patient’s risk profile and the therapeutic objective. It is essential to consider a history of gastrointestinal disease, cardiovascular disease and renal dysfunction, as well as the expected duration of treatment. The decision should always prioritize the lowest effective dose for the shortest possible duration.
COX selectivity — clinical framework
NSAIDs differ in their relative selectivity for the COX-1 and COX-2 enzymes, which should be understood as a continuum rather than an absolute characteristic. Predominant COX-1 inhibition is associated with higher gastrointestinal risk, whereas greater COX-2 selectivity tends to reduce digestive toxicity but may increase cardiovascular risk, particularly in patients with established cardiovascular disease. Selectivity is dose-dependent and influenced by the clinical context.
Cardiovascular implications
In patients with high cardiovascular risk, particular caution is required with NSAIDs whose profile is closer to COX-2, such as diclofenac and coxibs, due to the increased risk of thrombotic events. In these contexts, when an NSAID is indispensable, options with a relatively more neutral cardiovascular profile and short-term use tend to be preferred.
Pharmacokinetic duration and cumulative exposure
Pharmacokinetic duration, often expressed as half-life, reflects cumulative exposure to the drug. Short-duration NSAIDs are generally more appropriate for transient symptomatic control, whereas long half-life NSAIDs increase the risk of adverse effects, particularly renal, gastrointestinal and cardiovascular events, especially in older adults and patients with comorbidities. It is important to note that half-life is not directly synonymous with duration of clinical effect.
Renal risk and special populations
The risk of acute kidney injury is higher in patients with chronic kidney disease, heart failure, dehydration or concomitant treatment with ACE inhibitors/ARBs and diuretics. In these contexts, NSAIDs should be avoided whenever possible or used with extreme caution, prioritizing short-duration drugs and renal function monitoring.
Practical interpretation of the table
This table provides an integrated overview of the COX selectivity pattern and pharmacokinetic duration of the main NSAIDs, facilitating rapid risk–benefit assessment in different clinical scenarios. It is not intended to establish rigid therapeutic choices, but rather to support informed clinical decision-making, always adapted to the individual patient profile.
Final message
NSAID use should be individualized, integrating gastrointestinal, cardiovascular and renal risk, as well as the expected duration of treatment. This tool is intended as clinical decision support and does not replace medical judgement or consultation of the SmPC for each drug.
